PlexusDx vs Alan Meds: GLP-1 Pricing and Plans Compared Head-to-Head

Last reviewed: September 7, 2026 Last updated: September 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

Alan Meds publishes two conflicting semaglutide pricing structures on official pages captured the same day—one product page shows a buy-one-get-one promotional offer requiring $315 upfront for two months (an effective $158 per month if renewable), while a separate official resource page states $297 first month, then $397 per month thereafter. Under the higher $297/$397 structure, PlexusDx month-to-month semaglutide at $189 saves $2,396 over twelve months (our calculation). Under the lower BOGO scenario—if that offer renews indefinitely, which is undocumented—PlexusDx's six-month commitment plan at $149 per month costs $108 less per year than the promotional rate (our calculation). Alan Meds offers no verified tirzepatide pricing; that figure is hidden behind intake, preventing medication comparison beyond semaglutide. The pricing conflict on Alan Meds' own official pages means confirming the actual rate at checkout is essential.

At-a-glance comparison

Alan Meds pricing captured September 4, 2026; PlexusDx pricing captured September 7, 2026. Alan Meds BOGO offer requires $315 upfront prepayment for two-month supply; renewable status undocumented.

Semaglutide injection: conflicting price structures and 12-month calculations

Alan Meds presents two distinct pricing structures for compounded semaglutide injection on official pages captured the same day (September 4, 2026). One product page shows a buy-one-get-one promotional offer requiring $315 upfront for a two-month supply—an effective rate of $158 per month if that promotional structure renews every two months. A separate official resource page on the same domain states $297 first month, then $397 per month thereafter. Both pages were live and accessible on the same capture date, and no documentation explains which structure applies at checkout or whether the BOGO offer is a one-time promotion or a renewable billing model.

PlexusDx publishes transparent semaglutide injection pricing with three commitment tiers: $189 per month on month-to-month terms, $169 per month on a three-month commitment, and $149 per month on a six-month commitment. Each tier carries the same rate at every dose; there are no first-month discounts, hidden refill jumps, or promotional pricing that reverts to a higher ongoing rate.

Scenario A: Alan Meds BOGO offer at $158/month effective (if renewable)

If Alan Meds' buy-one-get-one promotional offer renews indefinitely at the same $315-per-two-months structure—a scenario that is undocumented—the effective monthly rate would remain $158. Over twelve months, that scenario would total $1,896 (our calculation: 12 months × $158 per month effective). PlexusDx month-to-month at $189 per month totals $2,268 over twelve months (our calculation), a difference of $372 more per year than the renewable BOGO scenario. PlexusDx's three-month commitment at $169 per month totals $2,028 over twelve months (our calculation), $132 more per year than the renewable BOGO scenario. PlexusDx's six-month commitment at $149 per month totals $1,788 over twelve months (our calculation), which is $108 less per year than the Alan Meds BOGO scenario if that offer renews without interruption.

The BOGO scenario requires confirming at checkout whether the promotional offer renews, whether it reverts to standard pricing after the first two months, and what the standard ongoing rate would be if the promotion ends.

Scenario B: Alan Meds $297 first month, $397 thereafter

Under the pricing structure shown on Alan Meds' official resource page—$297 for the first month, then $397 per month for subsequent refills—the twelve-month total would be $4,664 (our calculation: $297 + eleven months × $397). PlexusDx month-to-month at $189 per month totals $2,268 over twelve months, a savings of $2,396 per year (our calculation). PlexusDx's three-month commitment at $169 per month totals $2,028 over twelve months, a savings of $2,636 per year (our calculation). PlexusDx's six-month commitment at $149 per month totals $1,788 over twelve months, a savings of $2,876 per year (our calculation).

Under this scenario, PlexusDx delivers a substantial cost advantage at every commitment tier.

Tirzepatide and other formulations: evidence gaps

Alan Meds mentions compounded tirzepatide injection and oral semaglutide as available products, but neither formulation displays verified checkout pricing in the captured research. Tirzepatide pricing is hidden behind the intake form, preventing medication-level cost comparison. No oral tirzepatide or microdose GLP-1 maintenance option is documented for Alan Meds.

PlexusDx publishes transparent pricing for all formulations. Compounded tirzepatide injection costs $289 per month on month-to-month terms, $269 per month on a three-month commitment, and $249 per month on a six-month commitment. Oral semaglutide (compounded capsules) costs $289 per month month-to-month, $269 per month on three-month terms, and $249 per month on six-month terms. Oral tirzepatide capsules cost $349 per month month-to-month, $299 per month on three-month terms, and $279 per month on six-month terms. A microdose GLP-1 maintenance protocol is available at $129 per month on month-to-month terms only.

Decision factors and service-model differences

Price transparency and predictability

PlexusDx publishes one flat rate for each formulation and commitment tier; the advertised price equals the ongoing price at every refill. There are no first-month promotional discounts that revert to higher refill rates, no hidden membership fees, and no checkout surprises. Alan Meds' semaglutide pricing conflict—two official structures published simultaneously—creates uncertainty that requires confirmation at checkout. Tirzepatide pricing is unavailable before intake submission.

Formulation breadth

PlexusDx offers five distinct compounded GLP-1 protocols: semaglutide injection, tirzepatide injection, oral semaglutide, oral tirzepatide, and a microdose maintenance option. Every formulation carries published pricing. Alan Meds documents semaglutide injection with conflicting prices and mentions tirzepatide injection and oral semaglutide availability, but verified pricing is limited to semaglutide injection (with the noted conflict).

Commitment flexibility

PlexusDx provides three commitment tiers for most formulations—month-to-month, three-month, and six-month—allowing cost optimization based on tolerance confidence and budget preference. Alan Meds' BOGO offer requires $315 upfront for two months, which functions as a prepaid commitment; the renewable status of that structure is undocumented, and whether a month-to-month option exists under the $297/$397 pricing structure is unclear from the captured evidence.

Service inclusions

Both providers bundle provider consultation, prescription, medication, and shipping into their published rates. Neither charges a separate membership fee. PlexusDx explicitly states that one flat rate covers the provider visit, prescription, medication, and shipping with no separate line items. Alan Meds' BOGO offer page states that the $315 prepaid amount includes consult, medication, and shipping.

Choose Alan Meds if…

You verify at checkout that the buy-one-get-one promotional offer at $315 for two months ($158 per month effective) renews indefinitely without reverting to the higher $297/$397 structure, and you are comfortable with the $315 upfront prepayment requirement every two months. Under that scenario—if confirmed—Alan Meds would deliver a lower per-month rate than PlexusDx month-to-month or three-month plans, though PlexusDx's six-month commitment would still cost $108 less per year (our calculation). The pricing conflict on official pages and the lack of verified tirzepatide pricing mean you should expect to confirm every cost detail at checkout or during intake.

Choose PlexusDx if…

You want published, predictable pricing with no promotional-to-refill jumps, no conflicting official figures, and transparent commitment tiers that let you optimize cost against flexibility. If Alan Meds' actual ongoing rate follows the $297/$397 structure documented on their official resource page, PlexusDx's month-to-month semaglutide at $189 saves $2,396 over twelve months (our calculation), and the six-month commitment at $149 per month saves $2,876 per year (our calculation). You want access to tirzepatide injection, oral semaglutide, oral tirzepatide, or a microdose maintenance option with published pricing, or you prefer a provider with verified Trustpilot rating (PlexusDx holds 4.3 stars with 79% five-star reviews and 83% four stars or higher, captured September 9, 2026).

Methodology and freshness

This comparison draws on Alan Meds' official product pages and resource documentation captured September 4, 2026, and PlexusDx's published pricing captured September 7, 2026. Alan Meds pricing was documented from two official pages showing conflicting structures; no payment was submitted, and the research pass stopped before checkout verification, meaning the actual billing model at purchase requires confirmation. Tirzepatide pricing for Alan Meds was not captured because it is hidden behind the intake form. All twelve-month cost calculations are our calculations based on the documented per-month rates and stated commitment structures. We applied like-for-like comparison rules: month-to-month against month-to-month, prepaid per-month equivalents labeled as prepaid. The Alan Meds buy-one-get-one offer is labeled as a promotional prepaid structure requiring $315 upfront; we calculated the effective $158 per-month rate but noted that renewable status is undocumented. Review ratings for PlexusDx were captured from Trustpilot on September 4, 2026. Alan Meds' Trustpilot profile was identified but rating and volume were not captured in this research pass.

Frequently Asked Questions

Which Alan Meds semaglutide price is correct—the $315 BOGO offer or the $297/$397 structure?

Both pricing structures appear on official Alan Meds pages captured the same day (September 4, 2026). One product page shows a buy-one-get-one promotional offer requiring $315 upfront for two months; a separate official resource page states $297 first month, then $397 per month. The research pass did not reach checkout, so confirming which structure applies—and whether the BOGO offer renews or is a one-time promotion—requires contacting Alan Meds or completing intake and checkout.

Does PlexusDx charge more after the first month?

No. PlexusDx publishes one flat rate for each medication and commitment tier; the advertised price equals the ongoing refill price. Semaglutide injection costs $189 per month on month-to-month terms, $169 per month on three-month terms, and $149 per month on six-month terms—the same rate at intake, first refill, and every subsequent refill. There are no promotional discounts that revert to higher ongoing rates.

Can I see Alan Meds' tirzepatide price before starting intake?

No verified tirzepatide price for Alan Meds was captured in this research pass; that figure is hidden behind the intake form. Alan Meds mentions compounded tirzepatide injection as available, but checkout-verified pricing was not documented. PlexusDx publishes tirzepatide injection pricing on its product pages: $289 per month month-to-month, $269 per month on three-month terms, and $249 per month on six-month terms.

What is the true twelve-month cost difference between the two providers?

It depends on which Alan Meds pricing structure applies. If the buy-one-get-one offer renews indefinitely at $158 per month effective, PlexusDx month-to-month at $189 per month costs $372 more per year, but PlexusDx's six-month plan at $149 per month costs $108 less per year (our calculations). If Alan Meds' actual rate follows the $297 first month / $397 thereafter structure, PlexusDx month-to-month saves $2,396 per year and the six-month plan saves $2,876 per year (our calculations). Confirming the ongoing rate at checkout is essential.

Do both providers offer month-to-month billing with no long-term commitment?

PlexusDx offers month-to-month billing at $189 per month for semaglutide injection and $289 per month for tirzepatide injection, with no upfront commitment required. Alan Meds' buy-one-get-one promotional offer requires $315 upfront for two months, functioning as a prepaid commitment. Whether Alan Meds offers a true month-to-month option—and at what rate—is not documented in the captured evidence; the $297/$397 structure does not specify billing frequency or cancellation terms.

Sources

• PlexusDx official product pages and pricing (accessed September 7, 2026)
• Alan Meds semaglutide product page showing $315 buy-one-get-one promotional offer (accessed September 4, 2026)
• Alan Meds official resource page stating $297 first month, $397 thereafter for semaglutide (accessed September 4, 2026)
• Alan Meds website references to tirzepatide and oral semaglutide availability (accessed September 4, 2026)
• Trustpilot profile for PlexusDx, 4.3-star rating with 79% five-star reviews (accessed September 9, 2026)

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. PlexusDx works with licensed 503A compounding pharmacies. A licensed clinician determines whether a prescription is appropriate for an individual patient.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.